Am Klopferspitz 19
82152 Martinsried, de
+49 (89) 70096199-14
Viral vectors for novel cell models, gene therapy and vaccine development gain further funds from private investors
SIRION Biotech GmbH closes new financing round with additional investors
In its 6th year, the company has accelerated its growth dynamics with over 100 clients conducting discovery and research in industry and academia: all signs point to a high time for working with strategic cell models, close to reality. In addition, viral vectors are increasingly being used for novel vaccines and gene therapies. The first gene therapy application has recently been approved in Europe last November. One of SIRION's core competences is the design of de novo viral vectors and subsequently of custom cell models. The company has also developed Ad19a, a novel vector envelope, that shows superior performance in animal and human organisms, transducing cell types that are immunologically relevant.
Stemming from its fee-for-service business the company has experienced a wide variety of applications in over 300 single projects and accesses a large science network. Individual leads with high clinical potential will be pursued in collaborations to which the company contributes its scientific competence and GLP facility. About half a dozen such collaborations have already been initiated or are close to being executed.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.